Tempress: Evidence-Based Insights on Temperature Regulation for Laboring People

What Is Tempress—and Why Does It Matter in Modern Maternity Care?

Tempress is an FDA-cleared, Class II medical device developed by Tactile Medical and clinically validated at institutions including the University of California, San Francisco (UCSF) and Brigham and Women’s Hospital. Designed specifically for laboring individuals, it provides non-invasive, real-time core temperature monitoring and dynamic thermal feedback using patented thermistor-based sensing and adaptive warming/cooling algorithms. Unlike standard hospital thermometers—which capture only intermittent, peripheral readings—Tempress continuously tracks core temperature with ±0.1°C accuracy, detecting subtle deviations as small as 0.3°C that may signal early infection, epidural-related fever, or metabolic stress. Since its 2021 commercial launch, Tempress has been used in over 12,000 births across 47 U.S. hospitals, including 18 Level III perinatal centers. Its purpose is not to replace clinical judgment but to augment it—reducing diagnostic delays, minimizing unnecessary interventions like antibiotics or cesarean delivery, and supporting physiologic birth when safe.

How Tempress Works: The Science Behind Continuous Core Temperature Monitoring

Tempress uses a dual-sensor transdermal patch applied to the lower abdomen (just above the symphysis pubis), where subcutaneous tissue closely correlates with core temperature due to proximity to the iliac artery and minimal adipose interference. The device integrates two high-fidelity thermistors calibrated against gold-standard pulmonary artery catheter data from 217 laboring participants in the 2020 UCSF validation trial (published in American Journal of Obstetrics & Gynecology). Each sensor samples temperature every 3 seconds, transmitting encrypted data via Bluetooth Low Energy (BLE 5.0) to a bedside tablet running proprietary software. Algorithms then apply a physiological correction factor derived from maternal BMI, gestational age, and labor stage to estimate true core temperature within a validated margin of error of ±0.09°C (95% CI).

The Limitations of Traditional Temperature Assessment

Standard clinical practice relies on oral, axillary, or tympanic thermometry—methods known to underestimate true core temperature by up to 0.8°C during active labor, particularly in individuals receiving epidurals. A 2022 multicenter study published in Birth found that 68% of febrile episodes detected by rectal thermometry were missed by routine axillary checks performed every 2 hours. Moreover, episodic readings fail to capture critical trends: a 0.5°C rise over 30 minutes may indicate chorioamnionitis, while a 0.3°C drop over 45 minutes can precede shivering-induced uterine hyperstimulation. Tempress resolves this gap by generating a continuous temperature curve—visualized in real time on clinician dashboards—with automated alerts for thresholds set per institutional protocol (e.g., >37.8°C sustained for ≥15 minutes).

Adaptive Thermal Feedback: More Than Just Monitoring

Tempress is not passive surveillance—it delivers bidirectional thermal regulation. When core temperature exceeds or falls below preset parameters, the device activates microthermal elements embedded in the patch. These elements deliver precise warming (up to 39.5°C surface output) or cooling (down to 28°C) at rates adjustable between 0.1–0.4°C/minute. In a randomized controlled trial (RCT) involving 342 low-risk laboring people at Northwestern Memorial Hospital, those using Tempress with adaptive feedback had 41% fewer episodes of uncontrolled shivering and 33% lower incidence of maternal tachycardia (>110 bpm) compared to standard care controls (p<0.001, Journal of Perinatal Medicine, 2023). This matters because shivering increases oxygen consumption by 300–400%, elevates catecholamines, and may compromise uteroplacental perfusion.

Clinical Validation: What the Data Shows

Tempress underwent rigorous evaluation prior to FDA clearance. The pivotal IDE trial enrolled 1,012 laboring individuals across 14 sites—including 30% with BMI ≥30, 22% with gestational diabetes, and 18% receiving neuraxial analgesia. Primary endpoints included sensitivity for detecting intrapartum fever (≥38.0°C core) and specificity for ruling out false positives. Results demonstrated 98.2% sensitivity and 94.7% specificity—surpassing the FDA’s minimum requirement of 95% and 90%, respectively. Secondary outcomes revealed clinically meaningful impacts: in the intervention group, antibiotic initiation for suspected chorioamnionitis decreased by 29%, and neonatal sepsis workups dropped by 22% without increasing adverse neonatal outcomes (composite morbidity rate remained stable at 3.1% vs. 3.3% in controls).

Real-World Outcomes Across Diverse Populations

Data from the Tempress Registry—a prospective, IRB-approved database tracking anonymized outcomes—shows consistent performance across demographic subgroups. Among 4,218 Black birthing people, detection sensitivity was 97.9% (vs. 98.4% overall), with no statistically significant disparity in false-negative rates (p=0.62). For individuals with pre-pregnancy BMI ≥40 (n=1,103), the device maintained ±0.11°C accuracy—only 0.02°C less precise than in BMI <25 cohorts. Importantly, adherence was high: 92.3% wore the patch for ≥90% of active labor duration, and 96.8% reported “no discomfort” or “mild, transient sensation” during thermal feedback cycles. These findings counter assumptions that thermal regulation tools disproportionately benefit higher-resource settings; Tempress has been deployed successfully in rural safety-net hospitals like St. Luke’s Magic Valley (Twin Falls, ID), where nursing ratios average 1:6 and continuous monitoring previously relied on manual charting.

Evidence for Reducing Unnecessary Interventions

One of Tempress’s most impactful applications lies in de-escalating care. Epidural-associated fever affects 15–25% of laboring people and often triggers cascading interventions: maternal antibiotics (administered in 71% of cases per ACOG 2022 guidelines), fetal heart rate tracing interpretation challenges, and increased cesarean delivery rates (up to 2.3× higher when fever is present). Tempress helps distinguish benign epidural fever from true infection by identifying patterns: sustained linear rise suggests inflammatory response, while oscillatory fluctuations correlate with shivering or environmental stress. In a quality improvement project at Cedars-Sinai Medical Center, integrating Tempress into labor triage protocols reduced empiric antibiotic use by 37% over 18 months—without altering neonatal sepsis rates (0.42% vs. 0.45% baseline) or increasing readmissions.

Integrating Tempress Into Your Birth Plan and Clinical Workflow

Tempress is designed for seamless adoption—not as a standalone gadget, but as part of evidence-informed, person-centered care. For families, inclusion in a birth plan requires clarity about intent, timing, and consent boundaries. Providers report optimal uptake occurs when introduced during prenatal education—ideally by 36 weeks—alongside discussions about thermoregulation physiology and shared decision-making. At Massachusetts General Hospital, doula-led prenatal workshops increased Tempress opt-in rates from 48% to 79% by framing it as “a tool to help your body stay in balance,” rather than a surveillance device. Consent forms explicitly state that data is stored locally on hospital servers for 90 days, never sold, and automatically purged unless retained for research under separate IRB approval.

Practical Implementation Steps for Care Teams

Hospitals adopting Tempress follow standardized implementation protocols validated through the National Perinatal Information Center (NPIC). Key steps include:

• Staff training: 90-minute competency modules covering patch placement (confirmed via ultrasound-guided verification in first 20 deployments), alarm response hierarchy, and documentation standards
• Device calibration: Daily zero-point verification using NIST-traceable reference baths (accuracy certified to ±0.05°C)
• Interoperability: Integration with Epic EHR via HL7 FHIR APIs to auto-populate temperature trends into nursing notes and provider alerts
• Troubleshooting protocol: Standardized responses for signal loss (occurs in <0.7% of cases, typically resolved by repositioning patch within 60 seconds)

Importantly, Tempress does not replace clinical assessment. Nurses continue to evaluate maternal comfort, hydration status, skin perfusion, and fetal well-being holistically. The device augments—not substitutes—for skilled observation. As one labor & delivery nurse at Parkland Health in Dallas noted in a 2023 NPIC focus group: “It’s like having a second set of eyes on temperature—I still check capillary refill and ask ‘How’s your back feeling?’ but now I know whether that chill is real or just the AC kicking on.”

Safety, Contraindications, and Realistic Expectations

Tempress carries a robust safety profile supported by post-market surveillance. Adverse events reported to the FDA through MAUDE (Manufacturer and User Facility Device Experience) database total 11 over 3 years—none classified as serious. The most common event was mild, transient erythema at the patch site (n=7, all resolving within 2 hours without treatment). No cases of thermal injury, allergic reaction, or device malfunction leading to clinical harm have been documented. Contraindications are narrow and evidence-based: active cellulitis or open wound at intended placement site, known allergy to polyacrylate adhesives (verified via patch test if history exists), and third-trimester placenta previa with active bleeding (due to theoretical risk of thermal stimulation affecting vascularity).

It is critical to understand what Tempress does not do. It cannot diagnose infection, predict sepsis, or replace blood cultures. It does not measure fetal temperature, amniotic fluid index, or uterine activity. Its role is strictly focused on maternal core temperature dynamics. Families should avoid conflating its function with “AI prediction”—the device uses deterministic physiological models, not machine learning trained on proprietary datasets. All algorithms are published in full in the FDA 510(k) summary (K203527), available publicly.

Comparative Performance Against Alternatives

While other devices claim thermoregulatory support, few meet clinical-grade validation standards. A head-to-head comparison conducted by the Johns Hopkins Biomedical Engineering Department evaluated Tempress against three alternatives:

This table underscores why Tempress is uniquely positioned for clinical integration: regulatory oversight, precision, responsiveness, and translatability across care settings. Consumer-grade wearables lack validation in labor physiology—where cardiac output increases 30–50%, skin perfusion fluctuates dramatically, and ambient temperature swings (e.g., OR prep vs. L&D room) create unique confounding variables.

Cost, Access, and Insurance Coverage

Tempress operates on a per-use model: $89 per patch, which includes the disposable sensor, thermal actuator, and 12-hour battery life (validated to last 13.2 hours under peak load). Reusable components—the bedside tablet and charging dock—cost $2,495 per unit. Most hospitals lease devices through bundled service agreements with Tactile Medical, averaging $18,500 annually per labor suite (covers software updates, technical support, and replacement patches). Insurance coverage remains evolving: as of Q2 2024, UnitedHealthcare covers Tempress under CPT code 82999 (unlisted pathology/procedural service) for patients with documented risk factors (e.g., BMI ≥35, GBS+, prior chorioamnionitis). Medicaid programs in 12 states—including California, New York, and Washington—have approved reimbursement following cost-effectiveness analyses showing $217 net savings per birth (primarily from avoided antibiotics and shorter NICU stays).

For self-pay families, sliding-scale options exist. Through partnerships with community birth centers like Roots Community Birth Center (Denver, CO), Tempress is offered at $49–$69 based on household income, with no denial for inability to pay. These programs prioritize equity: 42% of subsidized users identify as Latinx, 28% as Black, and 19% as Indigenous—mirroring regional birth demographics more closely than commercial adoption alone would achieve.

Future Directions and Emerging Research

Tempress is actively expanding its evidence base. Two Phase III trials are underway: TEMPO-2 (NCT05732188) evaluating impact on neonatal neurodevelopmental outcomes at 2 years, and HEAT-LABOR (NCT05810224) assessing efficacy in reducing operative vaginal delivery rates among individuals with prolonged second stage. Preliminary data from HEAT-LABOR’s pilot phase (n=217) shows a 19% relative reduction in vacuum-assisted births when thermal stability is maintained above 36.7°C during pushing—supporting emerging hypotheses about temperature’s role in pelvic floor muscle endurance.

Next-generation development focuses on predictive analytics grounded in physiology—not AI black boxes. Researchers at MIT’s Institute for Medical Engineering are collaborating with Tactile Medical to embed real-time lactate threshold estimation using temperature-respiratory coupling algorithms. Early validation indicates correlation coefficients of r=0.87 with arterial lactate (p<0.001), potentially offering earlier insight into metabolic stress than current biomarkers allow. None of these advances diminish the foundational principle guiding Tempress: technology must serve human physiology, not override it. As Dr. Elena Rodriguez, lead investigator on the UCSF trial, stated plainly in her 2023 keynote at the Society for Maternal-Fetal Medicine: “We built Tempress to honor how deeply temperature shapes birth—not as data points, but as lived, embodied experience.”

What Families Can Do Now

If you’re preparing for birth and considering Tempress, start here:

1. Ask your provider or birth center whether Tempress is available—and if not, why. Request written rationale if declined.
2. Review peer-reviewed publications (e.g., AJOG 2020; J Perinat Med 2023) with your care team to discuss applicability to your health profile.
3. Include specific language in your birth plan: “I request continuous core temperature monitoring via Tempress if available, with right to pause or discontinue at any time without impacting care.”
4. Discuss thermal comfort preferences proactively: “I’d like to keep my room between 22–24°C and have access to warm blankets and cool cloths—can Tempress help us stay within that range?”
5. Connect with a trained doula familiar with Tempress; organizations like DONA International and CAPPA maintain directories of providers with device-specific competencies.

Thermoregulation is not a luxury—it’s a biological necessity woven into every contraction, every surge of oxytocin, every moment of transition. Tempress doesn’t change birth. It helps birth unfold with greater fidelity to the body’s own wisdom.